| Name | Title | Contact Details |
|---|
Agili-T Health Solutions is a Varennes, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Park View Care Ctr is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
“We are a part of the circle of life. It`s as touching and important to be a part of the end of life as it is to be at the beginning. We provide our patients dignity, comfort and quality of life at the end of their journey. Our job is so much more about life than death! Being present during this sacred time is truly and honor, a calling. “ -Jane, LPH Registered Nurse **** Chapters Health System is committed to enhancing the lives of those affected by advancing age or illness. Through our comprehensive system of healthcare choices, we deliver expert care and heartfelt support to guide the community during the aging and end-of-life journey. From hospice and palliative care for adults and children suffering with life-threatening or life-limiting illnesses to in-home and community-based services for frail but independent seniors, Chapters Health offers a wide range of support services along life`s ever-changing landscape. By providing choices, education and guidance, Chapters Health helps enhance the lives of those affected by advancing age or illness. Chapters Health System includes Chapters Health Palliative Care, Chapters Health Pharmacy, Chapters Health Staffing, Good Shepherd Hospice, HPH Home Health, HPH Hospice and LifePath Hospice.
Contec Vision is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.